Expected Moves

An expected update regarding capital adequacy metrics and broader Canadian regulatory stress tests. Markets will look for confirmation that BNS can sustain its dividend payouts without threatening its CET1 ratio. A clean bill of health supports a recovery to $79.50, while capital constraints would push the stock toward $79.50.

BNS will announce Q4 FY26 results alongside its formal FY27 guidance. Investors will dissect the international banking segment's growth trajectory under President Trump's trade framework. Strong forward guidance could unlock $83.00, while a cautious outlook on loan growth could reset the stock to $76.50.

BNS is scheduled to report Q3 FY26 earnings on August 25, 2026, with the market laser-focused on net interest margin (NIM) stability and credit loss provisioning. With shares trading near 52-week highs, flawless execution is required to break past $81.50, while any structural weakness in domestic lending could trigger a reversion toward the $77.00 floor.

The Q1 FY27 earnings release will provide a critical update on post-holiday credit card delinquencies and broader consumer health in Canada. Sustained loan performance could drive shares to $85.50, while a spike in credit loss provisions (PCLs) would trigger a defensive retreat to $79.50.